Welcome to our dedicated page for Resmed news (Ticker: RMD), a resource for investors and traders seeking the latest updates and insights on Resmed stock.
ResMed Inc. (NYSE: RMD, ASX: RMD) is a global leader in digital health and cloud-connected medical devices, focusing on innovative solutions that treat and prevent respiratory conditions like sleep apnea and COPD. By transforming patient care, ResMed empowers individuals to live healthier, higher-quality lives. Their diverse product portfolio includes flow generators, masks, and accessories designed to keep patients out of hospitals and manage chronic diseases effectively.
Operating in over 140 countries, ResMed’s cloud-connected medical devices provide data-driven insights used by patients, healthcare providers, and payers to deliver personalized and efficient healthcare. Their comprehensive out-of-hospital software platforms support professionals and caregivers, enhancing the quality of life and reducing healthcare costs. The company earns about two-thirds of its revenue from the Americas, with the remainder coming from Europe, Japan, and Australia.
In recent developments, ResMed successfully defended its intellectual property against a patent infringement claim by NYU, with the PTAB ruling in favor of ResMed on all challenged claims. This outcome underscores the company’s commitment to innovation, backed by over 9,500 issued or pending patents and designs.
ResMed also made headlines with a global field action to update guides for masks with magnets, ensuring user safety around medical implants. Their proactive approach and dedication to patient safety were evident as they addressed potential magnetic interference issues without necessitating a product recall.
Financially, ResMed continues to demonstrate strong growth. In the second quarter of fiscal year 2024, the company reported double-digit growth across its devices, masks, accessories, and residential care software businesses. This robust performance highlights ResMed’s strategic focus on expanding its product offerings and maintaining cost discipline.
ResMed's latest product launch, the AirCurve 11 series, further showcases their commitment to innovation. These bilevel PAP devices feature advanced digital technology to improve patient comfort and compliance, addressing challenges in CPAP therapy adaptation.
Continuing its leadership in respiratory care, ResMed actively participates in significant industry conferences such as the American Thoracic Society International Conference and SLEEP 2024, presenting crucial research on sleep disorders and their impact on health. This research supports the effectiveness of PAP therapy in reducing mortality and improving patient outcomes, solidifying ResMed’s role as a pioneer in the field.
With a clear focus on enhancing patient care through technology and innovation, ResMed is well-positioned to lead the expansion of sleep and respiratory health.
ResMed has acquired Leipzig-based mementor as of August 1, 2022, enhancing its digital sleep medicine portfolio in Germany. This strategic move integrates mementor’s somnio, a digital insomnia therapy solution, into ResMed's offerings, filling a significant care gap for patients suffering from insomnia. Somnio, which is the only permanently approved Digital Health Application (DiGA) for insomnia in Germany, is now available via prescription and eligible for reimbursement. This acquisition aims to expand access to effective sleep treatments and leverage ResMed's network for greater adoption.
ResMed (NYSE: RMD) has announced it will release its fourth-quarter fiscal year 2022 financial results on August 11, 2022, after the NYSE closes. Following this, management will host a webcast to discuss the outcomes and other material information. The webcast will be accessible at http://investor.resmed.com. A replay will be available shortly post-webcast, including a phone replay accessible until August 25. ResMed continues to focus on innovative solutions for chronic disease management, aiming to improve quality of life and reduce healthcare costs.
ResMed has announced the promotion of Lucile Blaise to President of Sleep & Respiratory Care, effective July 1, 2022. Blaise, with over 25 years in the medtech industry, previously served as Vice President for Western Europe. She has been influential in establishing payer market access for digital health in France and Belgium and advocates for data privacy and real-world evidence in healthcare. CEO Mick Farrell praised her commitment to patient-centric care and innovative leadership, highlighting her vital role in improving treatments for chronic diseases.
ResMed has announced its acquisition of MEDIFOX DAN, a leader in out-of-hospital software solutions in Germany, for approximately US$1 billion. This acquisition enhances ResMed's position as a significant U.S. provider of SaaS solutions, extending its offerings into outpatient therapy within Germany. MEDIFOX DAN's software solutions are crucial for care providers, and the transaction is expected to be accretive to ResMed's non-GAAP diluted earnings per share. The deal is anticipated to close by the end of December 2022, pending regulatory approvals.
ResMed (NYSE: RMD) CEO Mick Farrell is set to participate in a fireside chat at the Goldman Sachs Global Healthcare Conference on June 14, 2022, at approximately 1:20 p.m. PDT. This event will take place at the Terranea Resort in Rancho Palos Verdes, California. Interested parties can access a live webcast and a replay of the event via ResMed’s investor relations website, available for 12 hours post-event until June 14, 2023. ResMed focuses on innovative solutions for chronic disease management and aims to improve quality of life while reducing healthcare costs globally.
ResMed (NYSE: RMD) announced that Rob Douglas, its president and COO, will present at the William Blair Growth Stock Conference on June 8, 2022, at 9:20 a.m. CDT. The event will take place at the Loews Chicago Hotel, and investors can access more information and a live webcast through ResMed's investor site. A replay will be available approximately 12 hours after the event until September 6, 2022. ResMed focuses on innovative health solutions for chronic diseases, aiming to improve healthcare quality and reduce costs globally.
ResMed (NYSE: RMD) announced that CEO Mick Farrell will participate in a fireside chat at the Bernstein Strategic Decisions Conference on June 1, 2022, at 1:30 p.m. EDT in New York City. This event will provide insights into ResMed's strategies in healthcare innovation. A live webcast will be available on the company's investor relations website, with a replay accessible for one year after the event, until June 1, 2023. ResMed continues to be a leader in digital health technologies aimed at improving the quality of life for patients with chronic diseases.
ResMed's recent study highlights that sleep apnea patients can experience significant health benefits from just 2-3 hours of nightly PAP (positive airway pressure) usage. An analysis of 180,000 users found that each additional hour of PAP use reduces hospitalizations by 5% and emergency room visits by 4.4%. The study suggests that health systems should adapt their guidelines, as benefits extend up to 7 hours of use. Currently, Medicare requires a 4-hour minimum for adherence, which may hinder patient care. The study aims to reshape how healthcare professionals prescribe PAP therapy.
ResMed (NYSE: RMD) has announced the immediate departure of Jim Hollingshead, who served as the President of Sleep and Respiratory Care, after 12 years with the company. Rob Douglas has been appointed as interim President. CEO Mick Farrell acknowledged Hollingshead’s significant contributions to ResMed, particularly in digital health transformation. The transition aims to maintain strong leadership as the company positions itself for continued growth into 2025 and beyond.
ResMed reported a 12% year-over-year revenue increase to $864.5 million in Q3 2022, with a 14% rise on a constant currency basis. Operating profit grew by 5%, and diluted EPS reached $1.22. Despite a contraction in gross margins due to higher costs, strong demand in the sleep and respiratory care sector contributed to sales growth. The company faces supply chain challenges but maintains a positive outlook for its long-term strategy, aiming to impact 250 million lives by 2025.
FAQ
What is the current stock price of Resmed (RMD)?
What is the market cap of Resmed (RMD)?
What does ResMed Inc. specialize in?
Where does ResMed operate?
What are some of ResMed’s recent key developments?
How does ResMed ensure patient safety with its products?
What financial performance did ResMed report recently?
What innovations has ResMed introduced recently?
How does ResMed contribute to healthcare research?
What is ResMed’s approach to out-of-hospital care?
What kind of products does ResMed develop?
How does ResMed support its innovation?
